Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of NNC0480-0389 in Renal Impairment
NCT05015894Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NNC0480-0389 in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from zero to infinity. Started Aug 2021; status: completed.
02
Drugs
NNC0480-0389
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05015894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015894.